Search

Your search keyword '"Surasak Phuphanich"' showing total 3 results
Start Over Author "Surasak Phuphanich" Journal international journal of radiation oncology*biology*physics
3 results on '"Surasak Phuphanich"'

1. The Impact of Temozolomide on Post Radiation Therapy Progression Free Survival in Low Grade Glioma

Author

A.J. Mirhadi, Stephen L. Shiao, C. G. Patil, Jeremy Rudnick, B. Hakimian, Richard Tuli, A. Ortega, Emi J. Yoshida, J.L. Hu, and Surasak Phuphanich

Subjects
Oncology, Cancer Research, medicine.medical_specialty, Post-radiation, Radiation, Temozolomide, business.industry, Internal medicine, medicine, Radiology, Nuclear Medicine and imaging, Low-Grade Glioma, Progression-free survival, business, medicine.drug
Published
2015

2. Does Early Radiosurgery to Residual Enhancement Improve Outcome following Subtotal Resection of GBM?

Author

A.J. Mirhadi, Surasak Phuphanich, H.M. Sandler, Keith L. Black, Jeremy Rudnick, B. Hakimian, Ray M Chu, and John S. Yu

Subjects
Cancer Research, medicine.medical_specialty, Radiation, business.industry, medicine.medical_treatment, Subtotal Resection, Residual, Outcome (game theory), Radiosurgery, Oncology, medicine, Radiology, Nuclear Medicine and imaging, Medical physics, Radiology, business
Published
2009

3. Phase I study of intravenous bromodeoxyuridine used concomitantly with radiation therapy in patients with primary malignant brain tumors

Author

Surasak Phuphanich, Victor A. Levin, and Ellen M. Levin

Subjects
Adult, Male, Cancer Research, medicine.medical_specialty, Radiation-Sensitizing Agents, medicine.medical_treatment, Gastroenterology, chemistry.chemical_compound, Glioma, Internal medicine, medicine, Humans, Radiology, Nuclear Medicine and imaging, Platelet, Aged, Radiation, Leukopenia, business.industry, Brain Neoplasms, Therapeutic effect, Middle Aged, medicine.disease, In vitro, Surgery, Radiation therapy, Oncology, chemistry, Bromodeoxyuridine, Toxicity, Injections, Intravenous, Drug Evaluation, Female, medicine.symptom, business
Abstract

We report here the results of a Phase I study conducted to determine the toxicity and serum levels that could be tolerated by patients receiving i.v. bromodeoxyuridine (BUdR) concomitantly with radiation therapy. Because of severe thrombocytopenia and leukopenia that was produced in three patients treated by a 96 hour infusion of BUdR at a dose of 1.5 g/m2/24 hours, the dose was reduced to 0.8 g/m2/24 hours in these patients and the remaining 9 patients in the study group. Even at this dosage, myelotoxicity was observed. BUdR levels were measured by an isocratic high performance liquid chromatographic (HPLC) method developed for this study. Results of in vitro studies conducted by others suggest that serum levels produced in our patients by administration of doses of 0.6 to 0.8 g/m2/24 hours should be adequate to achieve a therapeutic effect.

Published
1984

Catalog

Books, media, physical & digital resources
See catalog results